Clinical Trial Update: The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and metabolism of GSK221149A in pregnant women at 30-36 weeks during pre-term labor; completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstetric Labor
• Premature Labor

Drugs mentioned

• GSK221149A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obstetric Labour, Premature | Phase 2 | Status: COMPLETED | Results posted: 2017-12-13